IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression

Journal of Immunology

Volumn 181, Issue 9, 2008, Pages 6051-6060

  Sainz Perez, Alexander ^a,d   Gary Gouy, Hélène ^a   Gaudin, Françoise ^a   Maarof, Ghyath ^a   Marfaing Koka, Anne ^b   De Revel, Thierry ^c   Dalloul, Ali ^a  

^a INSERM   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c PERCY MILITARY HOSPITAL   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; CYTOKINE ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 24; PERVANADATE; PIFITHRIN ALPHA; PROTEIN P53; PSTAT3 PROTEIN; STAT PROTEIN; STAT3 PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG; ZVAD PROTEIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; RECOMBINANT PROTEIN; STAT3 PROTEIN, HUMAN; THYMIDINE;

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA SYNTHESIS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; STRESS; TONSIL CELL; BIOSYNTHESIS; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; APOPTOSIS; B-LYMPHOCYTES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERLEUKIN-2; INTERLEUKINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; PHOSPHORYLATION; RECOMBINANT PROTEINS; STAT3 TRANSCRIPTION FACTOR; THYMIDINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58749111107     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.9.6051     Document Type: Article

References (53)

1. Kotenko, S. V. 2002. The family of IL-10-related cytokines and their receptors: related but to what extent? Cytokine Growth Factor Rev. 13: 223-240.
2. Renauld, J. C. 2003. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat. Rev. Immunol. 3: 667-676.
3. Jiang, H., J. J. Lin, Z. Z. Su, N. I. Goldstein, and P. B. Fisher. 1995. Subtraction hybridization identifies a novel melanoma-associated differentiation antigen, mda7, modulated during human melanoma differentiation growth and progression. Oncogene 11: 2477-2486. (Pubitemid 26023815)
4. Ellerhorst, J. A., V. G. Prieto, S. Ekmekcioglu, L. Broemeling, S. Yekell, S. Chada, and E. A. Grimm. 2002. Loss of MDA-7 expression with progression of melanoma. J. Clin. Oncol. 20: 1069-1074. (Pubitemid 34141852)
5. Ekmekcioglu, S., J. Ellerhorst, A. M. Mhashilkar, A. A. Sahin, C. M. Read, V. G. Prieto, S. Chada, and E. A. Grimm. 2001. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int. J. Cancer 94: 54-59. (Pubitemid 32801752)
6. Lebedeva, I. V., Z. Z. Su, Y. Chang, S. Kitada, J. C. Reed, and P. B. Fisher. 2002. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 21: 708-718.
7. Su, Z. Z., M. T. Madireddi, J. J. Lin, C. S. Young, S. Kitada, J. C. Reed, N. I. Goldstein, and P. B. Fisher. 1998. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl. Acad. Sci. USA 95: 14400-14405. (Pubitemid 28549379)
8. Poindexter, N. J., E. T. Walch, S. Chada, S., and E. A. Grimm. 2005. Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. J. Leukocyte Biol. 78: 745-752. (Pubitemid 41292097)
9. Bikah, G., J. Carey, J. R. Cialella, A. Tarakhovsky, and S. Bondada. 1996. CD5- mediated negative regulation of antigen-receptor-induced growth signals in B-1 B cells. Science 274: 1906-1909. (Pubitemid 26424770)
10. Gary-Gouy, H., P. Bruhns, A. Dalloul, M. Daëron, and G. Bismuth. 2000. The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling. J. Biol. Chem. 275: 548-556. (Pubitemid 30039017)
11. Gary-Gouy, H., J. Harriague, A. Dalloul, E. Donnadieu, and G. Bismuth. 2002. CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif. J. Immunol. 168: 232-239. (Pubitemid 34014123)
12. Gary-Gouy, H., J. Harriague, G. Bismuth, C. Platzer, C. Schmitt, and A. H. Dalloul. 2002. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 100: 4537-4543. (Pubitemid 35429695)
13. Gary-Gouy, H., A. Sainz-Perez, J.-B. Marteau, A. Marfaing-Koka, J. Delic, H. Merle-Béral, P. Galanaud, and A. Dalloul. 2007. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J. Immunol. 179: 4335-4344.
14. Sainz-Perez, A., H. Gary-Gouy, A. Portier, F. Davi, H. Merle-Beral, P. Galanaud, and A. Dalloul. 2006. High MDA-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia. Leukemia 20: 498-504. (Pubitemid 43291750)
15. Klein, U., Y. Tu, G. A. Stolovitzky, M. Mattioli, G. Cattoretti, H. Husson, A. Freedman, G. Inghirami, L. Cro, L. Baldini, et al. 2001. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194: 1625-1638. (Pubitemid 33126813)
16. Rosenwald, A., A. A. Alizadeh, G. Widhopf, R. Simon, R. E. Davis, X. Yu, L. Yang, O. K. Pickeral, L. Z. Rassenti, J. Powell, et al. 2001. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194: 1639-1647. (Pubitemid 33126814)
17. Sauane, M., R. V. Gopalkrishnan, I. Lebedeva, M. X. Mei, D. Sarkar, Z.-Z. Su, D.-C. Kang, P. Dent, S. Pretska, and P. B. Fisher. 2003. Mda7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. J. Cell. Physiol. 196: 334-345. (Pubitemid 36775881)
18. Lantz, O., C. Grillot-Courvalin, J.-P. Fermand, and J.-C. Brouet. 1985. Interleukin- 2-induced proliferation of leukemic human B cells. J. Exp. Med. 161: 1225-1230. (Pubitemid 15011337)
19. Touw, I., and B. Lowenberg. 1985. Interleukin 2 stimulates chronic lymphocytic leukemia colony formation in vitro. Blood 66: 237-240. (Pubitemid 15004811)
20. Friedmann, M. C., T.-S. Migone, S. M. Russell, and W. J. Leonard. 1996. Different interleukin 2 receptor β-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. Proc. Natl. Acad. Sci. USA 93: 2077-2082.
21. Frank, D. A., M. J. Robertson, A. Bonni, J. Ritz, and M. E. Greenberg. 1995. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc. Natl. Acad. Sci. USA 92: 7779-7783.
22. Paukku, K., and O. Silvennoinen. 2004. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. 6: 435-455. (Pubitemid 39550454)
23. 2 and vanadate stimulate protein tyrosine phosphorylation in intact cells. J. Biol. Chem. 265: 2896-2902.
24. Bromberg, J.F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, and J. E. Darnell Jr. 1999. Stat3 as an oncogene. Cell 98: 295-303.
25. Niu, G., K. L. Wright, Y. Ma, G. M. Wright, M. Huang, R. Irby, J. Biggs, J. Karras, D. Cress, D. Pardoll, et al. 2005. Role of stat3 in regulating p53 expression and function. Mol. Cell. Biol. 25: 7432-7440. (Pubitemid 41170107)
26. Zhong, Z., Z. Wen, and J. E. Darnell, Jr. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98.
27. Dumoutier, L., C. Leemans, D. Lejeune, S. V. Kotenko, and J. C. Renauld. 2001. Cutting edge: STAT activation by IL-19, IL-20, and mda-7 through IL-20 receptor complexes of two types. J. Immunol. 167: 3545-3549. (Pubitemid 32910793)
28. Wang, M., and P. Liang. 2005. Interleukin-24 and its receptors. Immunology 114: 166-170.
29. Komarov, P. G., E. A. Komarova, R. V. Kondratov, C. Christov-Tselkov, J. S. Coon, M. V. Chernov, and A. V. Gudkov. 1999. A chemical inhibitor of p53 that protect mice from the side effects of cancer therapy. Science 85: 1733-1737.
30. Toledo, F., and G. Wahl. 2006. Regulating the p53 pathway: in vitro hypothesis, in vivo veritas. Nat. Rev. Cancer 6: 909-923. (Pubitemid 44862676)
31. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. F. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 19: 817-825.
32. Zhan, Q., I. Bae, M. B. Kastan, and A. J. Fornace, Jr. 1994. The p53-dependent gamma-ray response of GADD45. Cancer Res. 54:2755-2760.
33. Efeyan, A., and M. Serrano. 2007. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6: 1006-1010. (Pubitemid 46708570)
34. Akasaki, Y., G. Liu, H. H. Matundan, H. Ng, X. Yuan, Z. Zeng, K. L. Black, and J. S. Yu. 2005. A peroxisome proliferator-activated receptor-γ agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J. Biol. Chem. 281: 6165-6174.
35. Defrance, T., B. Vanbervliet, J. P. Aubry, and J. Banchereau. 1988. Interleukin-4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2. J. Exp. Med. 168: 1321-1337. (Pubitemid 18264868)
36. Llorente, L., M. C. Crevon, S. Karray, T. Defrance, J. Banchereau, and P. Galanaud. 1989. Interleukin (IL) 4 counteracts the helper effect of IL-2 on antigen-activated human B cells. Eur. J. Immunol. 19: 765-769. (Pubitemid 19152948)
37. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
38. Vousden, K. H. 2002. Activaton of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602: 47-59. (Pubitemid 34311899)
39. Raman, V., A. Martensen, D. Reisman, E. Evron, W. F. Odenwald, E. Jaffee, J. Marks, and S. Sukumar. 2000. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405: 974-978. (Pubitemid 30435057)
40. bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis in CML. Blood 95: 1144-1152.
41. Xue, W., L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, and S. W. Lowe. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660. (Pubitemid 46232886)
42. Caudell, E. G., J. B. Mumm, N. Poindexter, S. Ekmekcioglu, A. M. Mhasilkar, X. H. Yang, M. W. Retter, P. Hill, and E. A. Grimm. 2002. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J. Immunol. 168: 6041-6046.
43. Ventura, A., D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder, and T. Jacks. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665. (Pubitemid 46232887)
44. Thornton, P. D., A. M. Gruszka-Westwood, R. A. Hamoudi, S. Atkinson, P. Kaczmarek, R. M. Morilla, B. L. Hilditch, R. A'Hern, E. Matutes, and D. Catovsky. 2004. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol. J. 5: 47-54. (Pubitemid 38262790)
45. el Rouby, S., A. Thomas, D. Costin, C. R. Rosenberg, M. Potmesil, R. Silber, and E. W. Newcomb. 1993. p53 gene mutation in chronic B-cell lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452-3459.
46. Baker, Z. J., A. C. Preisinger, J. M. Jessup, C. Paraskeva, S. Markowitz, J. K. Wilson, S. Hamilton, and B. Vogelstein. 1990. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50: 7717-7722.
47. Pharoah, P. D., N. E. Day, and C. Caldas. 1999. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br. J. Cancer 80: 1968-1973. (Pubitemid 29391282)
48. Kunz, S., K. Wolk, E. Witte, W. D. Doecke, H.-D. Volk, W. Sterry, K. Asadullah, and R. Sabat. 2006. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp. Dermatol. 15: 991-1004. (Pubitemid 44688369)
49. Chan, J. R., W. Blumenschein, E. Murphy, C. Diveu, M. Wiekowski, S. Abbondanzo, L. Lucian, R. Geissler, S. Brodie, A.B. Kimball, et al. 2006. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203: 2577-2587.
50. Adachi, M., M. Ishino, T. Torigoe, Y. Minami, T. Matozaki, T. Miyazaki, T. Taniguchi, Y. Hinoda, and K. Imai. 1997. Interleukin-2 induces tyrosine phosphorylation of SHP-2 through IL-2 receptor β chain. Oncogene 14: 1629-1633. (Pubitemid 27182848)
51. Migone, T. S., N. A. Cacalano, N. Taylor, T. Yi, T. A. Waldmann, and J. A. Johnston. 1998. Recruitement of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type-I-transformed T cells. Proc. Natl. Acad. Sci. USA 95: 3845-3850.
52. Kojima, K., M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff. 2006. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108: 993-1000. (Pubitemid 44154636)
53. Yu, H., and R. Jove. 2004. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4: 97-105. (Pubitemid 38198738)